- |||||||||| Sovaldi (sofosbuvir) / Gilead, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Preclinical, Journal: Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo. (Pubmed Central) - Feb 3, 2025
In summary, combining approved oral nucleoside analogs confers potent suppression of multiple alphaviruses in vitro and in vivo with enhanced control of viral genetic evolution in the face of antiviral drug pressure. These drug combinations may ultimately lead to the development of potent combinations of pan-family alphavirus inhibitors.
- |||||||||| Journal: EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION. (Pubmed Central) - Jan 12, 2025
These drug combinations may ultimately lead to the development of potent combinations of pan-family alphavirus inhibitors. The evaluation of hepatic elastography by the ARFI method before and after (6 - 9 months) successive treatment of hepatitis C in responders and non-responders led to the conclusion that the reduction of elastography parameters seems to be related to a decrease in hepatic inflammation rather than a reduction in fibrosis per se.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal, Real-world evidence, Real-world: Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China. (Pubmed Central) - Dec 11, 2024
Significant improvements were observed in the levels of total bilirubin, ALT, AST, albumin, globulin, albumin/globulin ratio, gamma-glutamyl transferase, alkaline phosphatase, platelet, fibrosis-4 (FIB-4), and aspartate transaminase to platelet ratio index (APRI) between baseline and EOT (p?<?0.05). SOF-based treatments achieved high virological and biochemical response rates in patients with HCV GT 6 infection.
- |||||||||| Journal: Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis. (Pubmed Central) - Dec 4, 2024
According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were daklinza, vocabria, doxorubicin, sovaldi, and ribavirin...Through an analysis of the FAERS database, it was observed that some pharmaceuticals do not adequately address the risk of HBV-R in their drug documentation. These findings could assist healthcare providers in promptly recognizing drug-induced HBV-R.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Sofosbuvir Polymorphs Distinguished by Linearly and Circularly Polarized Raman Microscopy. (Pubmed Central) - Nov 21, 2024
Moreover, circularly polarized Raman spectra and normalized degrees of circularity provided useful additional information and revealed several tentative markers of the different polymorphs of sofosbuvir. Although in some spectral regions the differences were less obvious, the results indicate that polarized Raman microscopy is a handy tool for discriminating between polymorphs of APIs and other compounds.
- |||||||||| Sovaldi (sofosbuvir) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Journal: Ligand-Enabled Cu-Catalyzed Stereoselective Synthesis of P-Stereogenic ProTides. (Pubmed Central) - Nov 13, 2024
Our protocol, featuring mild reaction conditions and broad applicability, enables the highly stereoselective synthesis of previously inaccessible (S,RP) and (R,SP)-ProTide derivatives. The practical utility of this method is demonstrated through the preparation of pharmaceutically relevant ProTide targets and mechanistic studies were conducted to elucidate the reaction pathway, offering significant advancements for drug development and pharmaceutical research.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan (clinicaltrials.gov) - Oct 21, 2024
P=N/A, N=318, Enrolling by invitation,
Overall, this study provides encouraging evidence for the potential of m-TOR inhibitor drugs as promising therapeutic agents for both HCC and HCV, warranting further investigation and optimization for clinical applications. Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- |||||||||| Sovaldi (sofosbuvir) / Gilead, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD), galidesivir (BCX4430) / BioCryst
Journal: Hydroxyl radical-induced C1'-H abstraction reaction of different artificial nucleotides. (Pubmed Central) - Sep 13, 2024
Subsequently, the structures of these complexes were further optimized by using the ?B97X-D dispersion-corrected density functional theory method and cc-PVTZ basis set in the aqueous medium. The IEFPCM method was used to model the aqueous medium.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Improving stereoselectivity of phosphotriesterase (PTE) for kinetic resolution of chiral phosphates. (Pubmed Central) - Aug 14, 2024
Other nations with high HCV prevalence might benefit from adopting similar multidimensional strategies, emphasizing prevention and treatment. Notably, W131M and I106A/W131M variants demonstrated successful preparation of pure (Sp)-diastereomer of remdesivir and sofosbuvir precursors within a remarkably short hydrolysis time (<20
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Regulation of NS5B Polymerase Activity of Hepatitis C Virus by Target Specific Phytotherapeutics: An In-Silico Molecular Dynamics Approach. (Pubmed Central) - Jul 23, 2024
The orientation of both arjunolic acid and sofosbuvir triphosphate (standard) within the active site was investigated through DCCM, PCA, and FEL analysis, indicating highly stable interactions of the lead arjunolic acid with the catalytic region of the NS5B enzyme. The findings of our current investigation suggest that bioactive therapeutics like arjunolic acid could serve as promising candidates for limiting the NS5B polymerase activity of the hepatitis C virus, offering hope for the future of HCV treatment.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
THE CHALLENGES OF TREATMENT OF PATIENT WITH HEPATITIS C VIRUS ASSOCIATED CIRRHOSIS AND SPINAL BRUCELLOSIS (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_963;
The findings of our current investigation suggest that bioactive therapeutics like arjunolic acid could serve as promising candidates for limiting the NS5B polymerase activity of the hepatitis C virus, offering hope for the future of HCV treatment. Many drugs can be used for the management of Brucellosis but Gentamycin and Streptomycin were contraindicated in decompensated cirrhosis, the patient was allergic to Sulfamethoxazole, Rifampicin can
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Analysis of articles on hepatitis C by scientific mapping: 1989-2022. (Pubmed Central) - Jul 17, 2024
Many drugs can be used for the management of Brucellosis but Gentamycin and Streptomycin were contraindicated in decompensated cirrhosis, the patient was allergic to Sulfamethoxazole, Rifampicin can This study provides valuable information about 40 years of academic knowledge on HCV.
- |||||||||| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Review, Journal: Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review. (Pubmed Central) - Jul 13, 2024
We believe that standardization of the recommendations of the Peruvian guidelines is imperative, including the new therapeutic strategies that have emerged in recent years. We also suggest conducting a cost effectiveness analysis in the Peruvian context to allow for the implementation of new antivirals, and to achieve a better control of hepatitis C in the country.
- |||||||||| yellow fever vaccine / iBio, Fraunhofer Institute for Molecular Biology and Applied Ecology, Oswaldo Cruz Foundation, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Sofosbuvir Off-label Treatment of Yellow Fever Patients During an Outbreak in Brazil, 2018: A Cohort Study. (Pubmed Central) - Jun 27, 2024
The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV. (Pubmed Central) - Jun 17, 2024
Our findings indicate that both drugs, especially sofosbuvir, exhibited reduced efficacy in neuronal cells compared to hepatic cells. These results should be taken into account in the development of direct-acting antivirals for HEV and their potency at extrahepatic replication sites.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Solid-state vibrational circular dichroism for pharmaceutical applications: Polymorphs and cocrystal of sofosbuvir. (Pubmed Central) - Jun 9, 2024
Our findings demonstrate that this approach reliably produces solid-state VCD spectra of model compounds. Although for large molecules with many atoms per unit cell, such as sofosbuvir, this approach has to be simplified and provides only a qualitative match, spectral calculations, and energy analysis helped us to decipher the observed differences in the experimental spectra of sofosbuvir.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: Novel Strategy for Screening Target Proteins by the Common Drugs?Sofosbuvir-Specific Profiling of HCV Patient Serum. (Pubmed Central) - May 28, 2024
Furthermore, four common differential proteins profiled by SOF material but not by POSS material were found to be identical and expressed consistently in both pooled serum samples and independent serum samples, which might potentially be biomarkers of HCV infection. Taken together, our study proposes a highly specific protein profiling strategy to display distinctive proteomic profiles, providing a novel idea for drug design and development.
- |||||||||| Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
PK/PD data, Journal: Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment. (Pubmed Central) - May 20, 2024
Sofosbuvir (SOF) plus RDV was demonstrated to be efficacious and safe in adults with active HCV infection, including those living with HIV (LWHIV), in the STORM-C-1 trial...Concomitant antiretroviral treatment (ART) increased RDV CL/F by 30%-60%, with efavirenz-based ART having the largest impact...While several covariates impact RDV CL/F and Vd/F, the effect on RDV exposures was not clinically relevant based on the efficacy data reported in this diverse Asian adult population. There were no meaningful drug-drug interactions in adults LWHIV on ART.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase III, Journal: Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir. (Pubmed Central) - May 5, 2024
To avoid a potentially severe course of the disease, sofosbuvir was used as antiviral treatment followed by the resolution of symptoms and serological response. As travelers with chronic diseases and immunosuppression will increasingly engage in long distance travel, this case demonstrates the importance of assessing patient history prior to the administration of live vaccines and points towards a possible therapeutic approach in those suffering from vaccine-associated YF.
- |||||||||| bemnifosbuvir (AT-527) / Atea Pharma
Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2241;
P2
C223H was found to be the primary BEM RAV in GT- 1b and multiple substitutions at other NS5B regions were required to confer meaningful resistance, suggesting a very high barrier to resistance for BEM. BEM is currently being evaluated in combination with ruzasvir (RZR), a highly potent pan-genotypic NS5A inhibitor, in a Phase 2 clinical trial (NCT05904470).
- |||||||||| Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Trial completion: REVOLUTIOn: Antiviral Agents Against COVID-19 Infection (clinicaltrials.gov) - Mar 22, 2024
P2/3, N=256, Completed,
This approach could be an important strategy for adoption towards the elimination of hepatitis. Active, not recruiting --> Completed
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Using Data to Develop Precision Medicine Approaches to Public Health Initiatives () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1894;
Socially Determined data can be used to understand variation in social risk to identify opportunities for effective public health interventions. Ultimately, this data-driven approach can improve outcomes, reduce costs, and drive health equity across the nation.
- |||||||||| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (clinicaltrials.gov) - Mar 6, 2024
P=N/A, N=60, Recruiting,
Ultimately, this data-driven approach can improve outcomes, reduce costs, and drive health equity across the nation. Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Transfer of Sofosbuvir/Velpatasvir Into Breast Milk (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_455;
Based on our findings, exposure to SOF/VEL via breastmilk is minimal and reassuring for infant safety and low potential for development of HCV resistance with perinatal transmission. Clinicians should consider expedited HCV treatment in the postpartum period during breastfeeding to improve linkage to HCV care.
- |||||||||| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Prevalence and Resistance Profiles of "Unusual" HCV Subtypes in Italy (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_454;
Clinicians should consider expedited HCV treatment in the postpartum period during breastfeeding to improve linkage to HCV care. 206 individuals (73%) were DAA-na
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Trial completion, Enrollment change, Trial completion date: Transmission of Chronic Hepatitis C in Pregnancy (clinicaltrials.gov) - Feb 8, 2024
P=N/A, N=40, Completed,
Researches investigating the effect of adding drugs that have antioxidant properties during sofosbuvir therapy are recommended. Unknown status --> Completed | N=150 --> 40 | Trial completion date: Sep 2020 --> Feb 2023
- |||||||||| bemnifosbuvir (AT-527) / Atea Pharma, Sovaldi (sofosbuvir) / Gilead
Review, Journal: Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase. (Pubmed Central) - Jan 24, 2024
BEM is approximately 10-fold more potent than sofosbuvir against HCV genotypes (GT) tested in vitro. When combined with a potent NS5A inhibitor, BEM is expected to be a promising once-daily oral antiviral for chronic HCV infection of all genotypes and fibrosis stages with potentially short treatment durations.
- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects. (Pubmed Central) - Jan 23, 2024
Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin...Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.
|
